[1]
|
Y. H. Ping, H. C. Lee, J. Y. Lee, P. H. Wu, L. K. Ho, C. W. Chi, M. F. Lu and J. J. Wang, “Anticancer Effects of Low-Dose 10-Hydroxycamptothecin in Human Colon Cancer,” Oncology Reports, Vol. 15, No. 5, 2006, pp. 1273- 1279.
|
[2]
|
R. P. Hertzberg, M. J. Caranfa and S. M. Hecht, “On the Mechanism of Topoisomerase I Inhibition by Camptothecin: Evidence for Binding to an Enzyme-DNA Complex,” Nucleic Acids Research, Vol. 21, No. 3, 1993, pp. 593- 600.
|
[3]
|
Y. H. Ling, R. Perez-Soler and M. T. Tseng, “Effect of DNA Topoisomerase I Inhibitor, 10-Hydroxycamptothecin, on the Structure and Function of Nuclei and Nuclear Matrix in Bladder Carcinoma MBT-2 Cells,” Anticancer Research, Vol. 13, No. 5A, 1993, pp. 1613-1617.
|
[4]
|
P. I. Yan, K. Jiang, R. Hou, Y. Gong, J. Lin, X. Sun and K. Tang, “Examination of Camptothecin and 10-Hydroxy-camptothecin in Camptothecaacuminata Plant and Cell Culture, and the Affected Yields Under Several Cell Culture Treatments,” Biocell Official Journal of the Sociedades Latinoamericanas de Microscopia Electronica et al., Vol. 34, No. 3, 2010, pp. 139-143.
|
[5]
|
ICH Steering Committee, “Impurities in New Drug Substances,” International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use, Chicago, 25 October 2006.
|
[6]
|
M. E. Wall, M. C. Wani, A. W. Nicholas, G. Mani Kumar and C. Tele, “Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs,” Journal of Medicinal Chemistry, 1993, Vol. 36, No. 18, pp. 2689-2700. doi:10.1021/jm00070a013
|
[7]
|
R. Rao and A. V. Rama Rao, “Method of Synthesizing the Key Intermediates for the Production of Camptothecin Derivatives,” US 0221358 A1, 2008.
|
[8]
|
J. Ma, Z. P. Jia, Q. Zhang, J. J. Fan, N. Jiang, R. Wang, H. Xie and J. Wang, “Liquid Chromatography Determination of 10-Hydroxycamptothecin in Human Serum by a Column-Switching System Containing a Precolumn with Re-stricted Access Media and its Application to a Clinical Pharmacokinetic Study,” Journal of Chromatography, Vol. 796, No. 1, 2003, pp. 195-200.
|
[9]
|
IFPMA, “Stability Testing of New Drug Substances and Drug Products Q1A(R2),” International Conference on Harmonization, Geneva, 2003.
|
[10]
|
ICH Steer-ing Committee, “Validation of Analytical Procedures,” International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use, 27 October 1994.
|